NEW DELHI : Biotechnology company Bharat Biotech that launched India's first intranasal vaccine against Covid-19 has sought market authorisation approval from Drugs Controller General of India (DCGI) for their intranasal heterologous booster, news agency ANI reported.
The report also stated that Bharat Biotech has also sought DCGI nod for phase three study of Intranasal vaccine in the 5-18 age group.
Recently, the Drugs Controller General of India(DCGI) on Tuesday has given emergency use authorization (EUA) to Bharat Biotech for the intranasal vaccine.
The regulator approved the vaccine for primary immunisation of those above 18 years, Union Health Minister Dr Mansukh Mandaviya tweeted. "Bharat Biotech International Limited (BBIL), a global leader in vaccine innovation and developer of vaccines for infectious diseases, today announced that iNCOVACC (BBV154), has received approval under Restricted Use in Emergency Situation for ages 18 and above," said Bharat Biotech in a statement "iNCOVACC is a recombinant replication-deficient adenovirus vectored vaccine with a pre-fusion stabilized spike protein.